STING1 and melanoma: Meanwhile, local treatment with Bifidobacterium effectively improved the cross-priming capacity of DCs by triggering the STING signaling pathway after anti-CD47 therapy, which provided a new mechanism in which intratumoral bacteria synergize with T cell-targeted immunotherapy.93 In addition, Akkermansia muciniphila-derived STING agonists could induce the production of type I interferon (IFN-I) by intratumoral monocytes, further inducing macrophage reprogramming and the crosstalk between NK and DC, thus improving the efficacy of the ICB of melanoma patients.44